• 대한핵의학회:학술대회논문집
• /
• 1991.05a
• /
• pp.160.2-161
• /
• 1991

• Korean Circulation Journal
• /
• v.54 no.4
• /
• pp.221-222
• /
• 2024

• Journal of Veterinary Clinics
• /
• v.17 no.1
• /
• pp.187-193
• /
• 2000

Fifteen adult Korea Jin-do dogs were studied by echocardiography to obtain the basic data of the imaging planes and normal references ranges to the aorta and pulmonary artery internal dimension. Measurements of aortic root internal dimension(AOID) and right pulmonary artery internal dimension (RPAID) were made at modified pulmonary arteries level short-axis view and left ventricular outflow tract long-axis view. The aortic root internal dimension and right pulmonary artery internal dimension at modified pulmonary arteries level short-axis view were 18.7$\pm$1.3mm (mean$\pm$SD) and 10.1$\pm$0.8mm, respectively. And RPAID/AOID was 0.5$\pm$0.1mm. The aortic root internal dimension and right pulmonary artery internal dimension at left ventricular outflow tract long-axis view were 19.3$\pm$1.6 mm and 10.7$\pm$1.3mm, respectively. And RPAID/AOID was 0.5$\pm$0.1mm. These results indicate that modified pulmonary arteries level short-axis view is useful planes to examine the aortic root and pulmonary arteries, and aortic root internal dimension is significantly higher(40~50%)than the right pulmonary artery internal dimension. Therefore measurements of aortic root internal and right pulmonary artery internal dimension can be used for monitoring dilation of pulmonary artery.

• Proceedings of the Korean Society of Veterinary Clinics Conference
• /
• 2006.05a
• /
• pp.193-193
• /
• 2006

• Proceedings of the Korean Society of Veterinary Clinics Conference
• /
• 2006.05a
• /
• pp.115-115
• /
• 2006

• Proceedings of the Korean Society of Veterinary Clinics Conference
• /
• 2008.10a
• /
• pp.151-151
• /
• 2008

• Tuberculosis and Respiratory Diseases
• /
• v.77 no.1
• /
• pp.34-37
• /
• 2014

Hypercoagulability disorders are commonly encountered in clinical situations in patients with a variety of cancers. However, several hypercoagulability disorders presenting as first symptoms or signs in cancer patients have rarely been reported. We herein described a case of a woman with adenocarcinoma of the lung presenting with deep vein thrombosis, nonbacterial thrombotic endocarditis, recurrent cerebral embolic infarction, and heart failure.

• Korean Circulation Journal
• /
• v.52 no.4
• /
• pp.304-319
• /
• 2022

Background and Objectives: De-escalation of dual-antiplatelet therapy through dose reduction of prasugrel improved net adverse clinical events (NACEs) after acute coronary syndrome (ACS), mainly through the reduction of bleeding without an increase in ischemic outcomes. Whether the benefits of de-escalation are sustained in highly thrombotic conditions such as ST-elevation myocardial infarction (STEMI) is unknown. We aimed to assess the efficacy and safety of de-escalation therapy in patients with STEMI or non-ST-segment elevation ACS (NSTE-ACS). Methods: This is a pre-specified subgroup analysis of the HOST-REDUCE-POLYTECH-ACS trial. ACS patients were randomized to prasugrel de-escalation (5 mg daily) or conventional dose (10 mg daily) at 1-month post-percutaneous coronary intervention. The primary endpoint was a NACE, defined as a composite of all-cause death, non-fatal myocardial infarction, stent thrombosis, clinically driven revascularization, stroke, and bleeding events of grade ≥2 Bleeding Academic Research Consortium (BARC) criteria at 1 year. Results: Among 2,338 patients included in the randomization, 326 patients were diagnosed with STEMI. In patients with NSTE-ACS, the risk of the primary endpoint was significantly reduced with de-escalation (hazard ratio [HR], 0.65; 95% confidence interval [CI], 0.48-0.89; p=0.006 for de-escalation vs. conventional), mainly driven by a reduced bleeding. However, in those with STEMI, there was no difference in the occurrence of the primary outcome (HR, 1.04; 95% CI, 0.48-2.26; p=0.915; p for interaction=0.271). Conclusions: Prasugrel dose de-escalation reduced the rate of NACE and bleeding, without increasing the rate of ischemic events in NSTE-ACS patients but not in STEMI patients.

• Proceedings of the Korean Society of Veterinary Clinics Conference
• /
• 2006.05a
• /
• pp.113-113
• /
• 2006

• Proceedings of the Korean Society of Veterinary Clinics Conference
• /
• 2007.10a
• /
• pp.589-589
• /
• 2007